Halozyme Therapeutics Stock News

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dixon Hubard Feinour & Brown Inc. VA boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,968 shares of the biopharmaceutical companys stock after purchasing an additional 5,000 shares during the []

Halozyme Therapeutics, Inc. (NEO:HALO) shares dropped 1.2% during mid-day trading on Tuesday . The stock traded as low as C$32.52 and last traded at C$32.88. Approximately 1,147,945 shares were traded during trading, an increase of 14% from the average daily volume of 1,004,275 shares. The stock had previously closed at C$33.28. Separately, Fundamental Research lowered []

Halozyme Therapeutics, Inc. (NEO:HALO)s stock price was down 1.2% during mid-day trading on Tuesday . The company traded as low as C$32.52 and last traded at C$32.88. Approximately 1,147,945 shares changed hands during trading, an increase of 14% from the average daily volume of 1,004,275 shares. The stock had previously closed at C$33.28. Separately, Fundamental []

Halozyme Therapeutics (NASDAQ:HALO) had its price target lowered by Wells Fargo & Company from $60.00 to $58.00 in a research report report published on Wednesday, PriceTargets.com reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical companys stock. Other equities analysts have also issued research reports about the company. JMP Securities raised []

First Hawaiian Bank bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,620 shares of the biopharmaceutical companys stock, valued at approximately $554,000. A number of other hedge funds have also recently modified their holdings []

Innate Pharma (NASDAQ:IPHA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Innate Pharma and Halozyme Therapeutics net margins, return on equity and return []

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares hit a new 52-week low on Thursday . The company traded as low as $36.04 and last traded at $36.09, with a volume of 4887 shares trading hands. The stock had previously closed at $36.82. A number of equities research analysts have weighed in on HALO shares. TheStreet upgraded shares []

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: 33rd Annual Piper Sandler Virtual He

Morgan Stanley cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 603,148 shares of the biopharmaceutical companys stock after selling 90,797 shares during the period. Morgan Stanley owned 0.42% of Halozyme Therapeutics worth $27,389,000 []

Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021.

Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million.  The increase is attributable to high

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2021 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 30.95% and 13.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Halozyme (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.